RYTM
Rhythm Pharmaceuticals Inc
92.80$
-0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.7% | +7.2% | +12.0% | +14.4% | +25.8% | -21.8% | +48.3% | +5.8% | +11.6% | +5.0% | +18.5% | – | |
| – | +34.0% | -13.2% | +5.0% | +29.9% | -1.1% | -3.7% | +51.9% | -0.8% | -12.7% | +49.0% | +24.8% | – | |
| – | +4.5% | +10.3% | +12.8% | +12.6% | +29.3% | -23.6% | +47.8% | +6.6% | +14.5% | +1.0% | +17.7% | – | |
| – | -11.0% | +329.8% | -76.6% | +26.4% | +8.5% | -10.2% | +14.4% | +8.8% | -8.7% | -0.7% | +4.1% | – | |
| – | +6.2% | +6.2% | +5.9% | -2.9% | +7.8% | +2.5% | +17.6% | +14.1% | +9.6% | +10.6% | +6.1% | – | |
| – | -2.8% | +161.9% | -59.1% | +10.1% | +8.2% | -4.1% | +16.0% | +11.6% | +1.1% | +5.8% | +5.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +44.5% | +4.5% | -3.2% | +13.9% | +3.9% | -0.7% | +7.5% | -18.5% | -2.7% | -0.7% | -0.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -46.7% | +53.1% | +59.7% | -171.8% | – | – | +321.3% | -67.1% | -127.9% | – | -18.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.